Evidence map›Paper›PMID 32763198›Full record

ArticleThe Lancet. Respiratory medicine2020

Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series.

Sarah Reagan-Steiner, Joy Gary, Eduard Matkovic, Jana M Ritter, Wun-Ju Shieh, Roosecelis B Martines, Angela K Werner, Ruth Lynfield, Stacy Holzbauer, Hannah Bullock and 15 more

Open access · greenAbstract read
In one paragraph

Article in The Lancet. Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. E-Cigarette or Vaping Product Use-Associated Lung Injury: A Comprehensive Review.International journal of environmental research and public health · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Vaping and Lung Inflammation and Injury.Annual review of physiology · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Identification of Gamma-Butyrolactone in JUUL Liquids.Journal of analytical toxicology · 2021
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 1 country.

Sarah Reagan-SteinerCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA. Electronic address: sor1@cdc.gov.
Joy GaryCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Eduard MatkovicCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Jana M RitterCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Wun-Ju ShiehCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Roosecelis B MartinesCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Angela K WernerNational Center for Environmental Health, Atlanta, GA, USA.
Ruth LynfieldMinnesota Department of Health, Saint Paul, MN, USA.
Stacy HolzbauerCenter for Preparedness and Response, Atlanta, GA, USA; Minnesota Department of Health, Saint Paul, MN, USA.
Hannah BullockSynergy America, Atlanta, GA, USA.
Amy M DenisonCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Julu BhatnagarCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Brigid C BollwegCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Mitesh PatelCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Mary E EvansNational Center for Injury Prevention and Control, Atlanta, GA, USA.
Brian A KingNational Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA, USA.
Dale A RoseCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Grant T BaldwinNational Center for Injury Prevention and Control, Atlanta, GA, USA.
Christopher M JonesNational Center for Injury Prevention and Control, Atlanta, GA, USA.
Vikram KrishnasamyNational Center for Injury Prevention and Control, Atlanta, GA, USA.
Peter A BrissNational Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA, USA.
David N WeissmanCenters for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, WV, USA.
Dana Meaney-DelmanNational Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA, USA.
Sherif R ZakiCenters for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA.
Lung Injury Response Pathology Working Group
National Center for Emerging and Zoonotic Infectious Diseases · USCenters for Disease Control and Prevention · USNational Center for Injury Prevention and Control · USNational Center for Chronic Disease Prevention and Health Promotion · USMinnesota Department of Health · USNational Center for Environmental Health · USNational Institute for Occupational Safety and Health · USSynergy America (United States) · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundSince August, 2019, US public health officials have been investigating a national outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI). A spectrum of histological patterns consistent with acute to subacute lung injury has been seen in biopsies; however, autopsy findings have not been systematically characterised. We describe the pathological findings in autopsy and biopsy tissues submitted to the US Centers for Disease Control and Prevention (CDC) for the evaluation of suspected EVALI.

methodsBetween Aug 1, 2019, and Nov 30, 2019, we examined lung biopsy (n=10 individuals) and autopsy (n=13 individuals) tissue samples received by the CDC, submitted by 16 US states, from individuals with: a history of e-cigarette, or vaping, product use; respiratory, gastrointestinal, or constitutional symptoms; and either pulmonary infiltrates or opacities on chest imaging, or sudden death from an undetermined cause. We also reviewed medical records, evaluated histopathology, and performed infectious disease testing when indicated by histopathology and clinical history.

findings21 cases met surveillance case definitions for EVALI, with a further two cases of clinically suspected EVALI evaluated. All ten lung biopsies showed histological evidence of acute to subacute lung injury, including diffuse alveolar damage or organising pneumonia. These patterns were also seen in nine of 13 (69%) autopsy cases, most frequently diffuse alveolar damage (eight autopsies), but also acute and organising fibrinous pneumonia (one autopsy). Additional pulmonary pathology not necessarily consistent with EVALI was seen in the remaining autopsies, including bronchopneumonia, bronchoaspiration, and chronic interstitial lung disease. Three of the five autopsy cases with no evidence of, or a plausible alternative cause for acute lung injury, had been classified as confirmed or probable EVALI according to surveillance case definitions.

interpretationAcute to subacute lung injury patterns were seen in all ten biopsies and most autopsy lung tissues from individuals with suspected EVALI. Acute to subacute lung injury can have numerous causes; however, if it is identified in an individual with a history of e-cigarette, or vaping, product use, and no alternative cause is apparent, a diagnosis of EVALI should be strongly considered. A review of autopsy tissue pathology in suspected EVALI deaths can also identify alternative diagnoses, which can enhance the specificity of public health surveillance efforts.

fundingUS Centers for Disease Control and Prevention.

Indexed as

Acute Lung InjuryAdultAutopsyBiopsyElectronic Nicotine Delivery SystemsFemaleHumansLungMaleUnited StatesVaping

Identifiers

PMID32763198
PMCPMC9477212
OpenAlexW3047426952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.